EBV-driven B-cell lymphoproliferative disorders: From biology, classification and differential diagnosis to clinical management

Experimental and Molecular Medicine

Volumn 47, Issue 1, 2015, Pages

  Ok, Chi Young ^a   Li, Ling ^a,b   Young, Ken H ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL TYPE CHRONIC ACTIVE EPSTEIN BARR VIRUS DISEASE; BURKITT LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS ASSOCIATED B CELL LYMPHOPROLIFERATIVE DISORDER; EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; INFECTIOUS MONONUCLEOSIS LYMPHADENITIS; LARGE CELL LYMPHOMA; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MORPHOLOGY; NONHUMAN; PATHOGENESIS; PLASMABLASTIC LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; REVIEW; VIRUS LATENCY; B LYMPHOCYTE; COMPLICATION; DISEASE MANAGEMENT; EPSTEIN BARR VIRUS INFECTION; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

B-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84928007798     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.82     Document Type: Review

References (120)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-703.
2. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985;35:35-42.
3. Castillo JJ, Reagan JL, Bishop KD, Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol 2014;165:300-315.
4. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. New Engl J Med 1984;310:1225-1230.
5. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984;81:4510-4514.
6. Li Q, Spriggs MK, Kovats S, Turk SM, Comeau MR, Nepom B et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol 1997;71:4657-4662.
7. Given D, Yee D, Griem K, Kieff E. DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol 1979;30:852-862.
8. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984;81:3806-3810.
9. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU.1. J Virol 1995;69:253-262.
10. Kieff ED, Rickinson AB (eds). Epstein-Barr Virus and Its Replication. Lippincott Williams and Wilkins: Philadelphia, PA, USA, 2006.
11. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M. The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 1994;205:596-602.
12. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963-11968.
13. Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999;286:300-303.
14. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. New Engl J Med 1998;338:1413-1421.
15. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-1115.
16. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996;70:8653-8659.
17. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003;278:3694-3704.
18. Roberts ML, Cooper NR. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998;240:93-99.
19. Eliopoulos AG, Waites ER, Blake SM, Davies C, Murray P, Young LS. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. J Virol 2003;77:1316-1328.
20. Everly DN Jr, Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004;78:13470-13478.
21. Laux G, Perricaudet M, Farrell PJ. A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 1988;7:769-774.
22. Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J Gen Virol 2006;87:1047-1074.
23. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 2003;45:1-36.
24. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995;2:155-166.
25. Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 2009;28:1471-1476.
26. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004;23:8619-8628.
27. Fish K, Chen J, Longnecker R. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 2014;123:530-540.
28. Rechsteiner MP, Bernasconi M, Berger C, Nadal D. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency. Trends Microbiol 2008;16:520-527.
29. Howe JG, Steitz JA. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci USA 1986;83:9006-9010.
30. Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993;82:619-624.
31. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J et al. Identification of virus-encoded microRNAs. Science 2004;304:734-736.
32. Xing L, Kieff E. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J Virol 2007;81:9967-9975.
33. Chen H, Huang J, Wu FY, Liao G, Hutt-Fletcher L, Hayward SD. Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. J Virol 2005;79:1724-1733.
34. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008;36:666-675.
35. Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, Hatzigeorgiou A et al. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 2010;285:33358-33370.
36. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009;11:1174-1184.
37. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog 2012;8:e1002484.
38. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 2010;6:e1001063.
39. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008;205:2551-2560.
40. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-κB pathway. Nucleic Acids Res 2008;36:6608-6619.
41. Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E et al. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J Virol 2012;86:6889-6898.
42. Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virusencoded EBNA2. Leukemia 2012;26:2343-2352.
43. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer-a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010;34:405-417.
44. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011;117:5835-5849.
45. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988;157:405-412.
46. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virusassociated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009;20:1472-1482.
47. Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003;187:527-533.
48. Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002;100:3415-3418.
49. Nakamura S, Jaffe ES, Swerdlow SH (eds). EBV Positive Diffuse Large B-Cell Lymphoma of the Elderly. International Agency for Research on Cancer (IARC): Lyon, France, 2008.
50. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003;27:16-26.
51. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013;122:328-340.
52. Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 2014;20:2338-2349.
53. Hofscheier A, Ponciano A, Bonzheim I, Adam P, Lome-Maldonado C, Vela T et al. Geographic variation in the prevalence of Epstein-Barr viruspositive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011;24:1046-1054.
54. Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV (+) and EBV (-) cases in Japanese population. Jpn J Cancer Res 2000;91:1233-1240.
55. Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007;13:5124-5132.
56. Park S, Lee J, Ko YH, Han A, Jun. HJ, Lee SC et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
57. Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S. Epstein-Barr viruspositive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010;41:352-357.
58. Montes-Moreno S, Odqvist L, Diaz-Perez JA, Lopez AB, de Villambrosia SG, Mazorra F et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol 2012;25:968-982.
59. Chan J K C, Aozasa K, Gaulard P (eds). DLBCL Associated with Chronic Inflammation. IARC: Lyon, France, 2008.
60. Iuchi K, Ichimiya A, Akashi A, Mizuta T, Lee YE, Tada H et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 1987;60:1771-1775.
61. Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002;20:4255-4260.
62. Petitjean B, Jardin F, Joly B, Martin-Garcia N, Tilly H, Picquenot JM et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol 2002;26:724-732.
63. Yamato H, Ohshima K, Suzumiya J, Kikuchi M. Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. Histopathology 2001;39:163-171.
64. Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K et al. Frequent p53 mutations at dipyrimidine sites in patients with pyothoraxassociated lymphoma. Cancer Res 1998;58:1105-1107.
65. Nishiu M, Tomita Y, Nakatsuka S, Takakuwa T, Iizuka N, Hoshida Y et al. Distinct pattern of gene expression in pyothorax-associated lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci 2004;95:828-834.
66. Stein H, Harris NL, Campo E (eds). Plasmablastic Lymphoma. IARC: Lyon, France, 2008.
67. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-1420.
68. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008;83:804-809.
69. Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15:1673-1679.
70. Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011;136:183-194.
71. Isaacson PG, Campo E, Harris NL (eds). Large B-Cell Lymphoma Arising in HHV8-Associated Multicentric Castleman Disease. IARC: Lyon, France, 2008.
72. Valera A, Balague O, Colomo L, Martinez A, Delabie J, Taddesse-Heath L et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34:1686-1694.
73. Said J, Cesarman E (eds). Primary Effusion Lymphoma. IARC: Lyon, France, 2008.
74. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-656.
75. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004;28:1401-1416.
76. Jones D, Ballestas ME, Kaye KM, Gulizia JM, Winters GL, Fletcher J et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. New Engl J Med 1998;339:444-449.
77. Said JW, Tasaka T, Takeuchi S, Asou H, de Vos S, Cesarman E et al. Primary effusion lymphoma in women: report of two cases of Kaposi's sarcoma herpes virus-associated effusion-based lymphoma in human immunodeficiency virus-negative women. Blood 1996;88:3124-3128.
78. Cobo F, Hernandez S, Hernandez L, Pinyol M, Bosch F, Esteve J et al. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. J Pathol 1999;189:288-293.
79. Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997;90:1186-1191.
80. Pan ZG, Zhang QY, Lu ZB, Quinto T, Rozenvald IB, Liu LT et al. Extracavitary KSHV-associated large B-cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol 2012;36:1129-1140.
81. Mullaney BP, Ng VL, Herndier BG, McGrath MS, Pallavicini MG. Comparative genomic analyses of primary effusion lymphoma. Arch Pathol Lab Med 2000;124:824-826.
82. Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R et al. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PELspecific transcripts. Blood 2003;101:4115-4121.
83. Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972;3:457-558.
84. Pittaluga S, Wilson WH, Jaffe ES (eds). Lymphomatoid Granulomatosis. IARC: Lyon, France, 2008.
85. Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M et al. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. Am J Surg Pathol 2001;25:1111-1120.
86. Taniere P, Thivolet-Bejui F, Vitrey D, Isaac S, Loire R, Cordier JF et al. Lymphomatoid granulomatosis-a report on four cases: evidence for B phenotype of the tumoral cells. Eur Respir J 1998;12:102-106.
87. Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979;43:360-373.
88. Guinee D Jr., Jaffe E, Kingma D, Fishback N, Wallberg K, Krishnan J et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994;18:753-764.
89. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46:218-223.
90. Leoncini L, Raphael M, Stein H, Harris NL, Jaffe E, Kluin PM (eds). Burkitt Lymphoma. IARC: Lyon, France, 2008.
91. Morrow RH, Kisuule A, Pike MC, Smith PG. Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria. J Natl Cancer Inst 1976;56(3):479-483.
92. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New Engl J Med 2006;354:2419-2430.
93. Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 2012;120:2240-2248.
94. Lenze D, Leoncini L, Hummel M, Volinia S, Liu CG, Amato T et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011;25:1869-1876.
95. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-120.
96. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012;44:1316-1320.
97. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44:1321-1325.
98. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832;17:68-114.
99. Delsol G, Brousset P, Chittal S, Rigal-Huguet F. Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. Am J Pathol 1992;140:247-253.
100. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-1450.
101. Hartmann S, Martin-Subero JI, Gesk S, Husken J, Giefing M, Nagel I et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 2008;93:1318-1326.
102. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012;120:3530-3540.
103. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, Figueroa V, Vega F, Younes A et al. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol 2013;162:336-347.
104. Swerdlow SH, Webber SA, Chadburn A, Ferry JA (eds). Post-transplant Lymphoproliferative Disorders. IARC: Lyon, France, 2008.
105. Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 1968;4:746-748.
106. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
107. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008;8:984-989.
108. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007;17:203-210.
109. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, Murty VV et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum Pathol 2007;38:315-325.
110. Djokic M, Le Beau MM, Swinnen LJ, Smith SM, Rubin CM, Anastasi J et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 2006;45:313-318.
111. Rinaldi A, Kwee I, Poretti G, Mensah A, Pruneri G, Capello D et al. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. Br J Haematol 2006;134:27-36.
112. Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 2013;13:1305-1316.
113. Rossi D, Gaidano G, Gloghini A, Deambrogi C, Franceschetti S, Berra E et al. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br J Haematol 2003;123:475-478.
114. Alsayed Y, Leleu X, Leontovich A, Oton AB, Melhem M, George D et al. Proteomics analysis in post-transplant lymphoproliferative disorders. Eur J Haematol 2008;81:298-303.
115. Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-636.
116. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. New Engl J Med 2003;349:2570-2572; discussion 2570-2572.
117. Sohani AR, Ferry JA, Chang PS, Abramson JS. Epstein-Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol 2010;28:e69-e72.
118. Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS et al. Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol 2009;22:1532-1540.
119. Kikuchi K, Miyazaki Y, Tanaka A, Shigematu H, Kojima M, Sakashita H et al. Methotrexate-related Epstein-Barr virus (EBV)-associated lymphoproliferative disorder-so-called 'Hodgkin-like lesion'-of the oral cavity in a patient with rheumatoid arthritis. Head Neck Pathol 2010;4:305-311.
120. Bhamidipati PK, Jabbour E, Konoplev S, Estrov Z, Cortes J, Daver N. Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine. Clin Lymphoma Myeloma Leuk 2013;13:342-346.